Th e evolution of homocysteine (Hcy) changes after acute myocardial infarction is still not elucidated. Serum Hcy concentration has been shown to increase between acute and convalescent period after myocardial infarction and stroke. Also a decrease in serum Hcy during acute phase was observed. It is still not clear whether the Hcy is a culprit or an innocent bystander in cardiovascular diseases. Addressing the discrepancies in Hcy changes in patients with acute myocardial infarction might give insight in Hcy role in cardiovascular diseases and off er implications both for the clinical interpretation and patients risk stratifi cation. Th e aim of the study was to evaluate serum Hcy concentration changes during early post myocardial infarction. Th e study included patients with AMI from the Clinics for Heart Diseases and Rheumatism at University of Sarajevo Clinics Centre. For Hcy analysis blood was collected on day and after the AMI onset. Serum Hcy concentration was determined quantitatively with fl uorescent polarisation immunoassay on AxSYM system. Cluster analysis revealed two groups of AMI patients with diff erent trends of serum Hcy changes. Increase in serum Hcy concentration was observed in (,) patients (AMI group), while in (,) patients a decrease was observed (AMI group). On day , patients in AMI group had signifi cantly higher mean Hcy concentration compared to AMI group of patients (,±, and ,±, μmol/L p<,). On day , no signifi cant diff erence in mean Hcy level between AMI and AMI group of patients was observed (,±, vs. ,±, μmol/L respectively). Signifi cant diff erences between AMI and AMI patients were observed in VLDLC levels and CK-MB activity on day .
The study was designed with the main intent to assess and explain the differences between athlete's heart syndrome and the heart of healthy non-athletes, and to distinguish between physiological and pathological heart condition. Prolonged athletic training causes changes in heart that are termed "athlete's heart syndrome". Athlete's heart diagnosis and related issues are a great challenge due to complementary morphological, functional and electro-physiological changes that may indicate both physiological and pathological condition. The study included 150 subjects, of those 100 were active athletes and 50 were in control group. The study protocol included one clinical examination, one electrocardiogram and one echocardiograph for each subject. Average age was 20,51+/-8,51 in the athletes and 21,48+/-2,53 in control group. Significantly higher average left ventricle (LV) mass (401,23 g vs. 143,23 g) and LV mass index (196,05 g/m2 vs. 83,98 g/m2) was found in the athletes (p<0,05). The study showed increased mass and wall thickness with usual inner dimensions of athlete's heart. Systolic and diastolic function of athlete's heart is normal. Athlete's heart with these features is a healthy heart.
Hypertension is a major risk factor for cardiovascular diseases; drugs that reduce blood pressure and simultaneously improve or reverse endothelian dysfunction, as nebivolol, may be advantageous in terms of cardiovascular protection. The objective of this study is to show the anti-hypertensive efficacy and safety of nebivolol (5 mg once a day) given to patients with arterial hypertension for 3 months. It should also provide information about drug's influence on laboratory tests--fasting blood glucose and serum cholesterol, triglyceride and creatinine concentrations. Six centers--Tuzla, Sarajevo, Mostar, Bihac, Zenica and Banja Luka participated in this prospective study with follow-up period of 3 months that included 3 visits. The study group consisted of 328 hypertensic patients. Results showed a significant decrease in both systolic and diastolic blood pressure and heart rate at the end of the study. Fasting blood glucose level and serum cholesterol, triglyceride and creatinine changed significantly during the study, with lower levels of all the tests. Nebivolol seems to be free from some of the problems that generally accompany not only the classical beta- blockers but sometimes also newer classes of antihypertensive drugs. With its high anti-hypertensive efficiency and safety, and presence of statically significant difference in laboratory tests and beneficial effects, absence of adverse interaction with glucose and lipid metabolism, patients treated with Nebivolol may show an optimal adherence to therapy.
The aim of this study was to investigate the relationship between benign joint hypermobility syndrome (BJHS) and FMS. Methods Thirty-four fibromyalgia patients and 30 healthy control subjects with a mean age of 32.6 ± 7.8 and 38.8 ± 11.1 years respectively, were recruited to the study. Data about demographical and clinical characteristics of the subjects including age, sex, widespread pain, number of specific tender points and associated symptoms were recorded. The joint hypermobility was evaluated depending on the Beighton score and the diagnosis of BJHS was considered according to the revised criteria for the diagnosis of BJHS (Brighton 1998). Results There were 2 male and 32 female subjects in each group. The mean number of tender points (14.7 ± 1.9 vs 2.5 ± 3.1), associated symptoms (7.1 ± 1.7 vs 2.5 ± 1.6) and Beighton score (3.4 ± 1.3 vs 1.7 ± 1.9) were significantly higher in the FMS group. The BJHS was present in 2 (5.8%) of FMS and 1 (2.9%) of the control subjects. Conclusion The fibromyalgia patients may be more hypermobile than the control subjects but BJHS is a different clinical entity having no relationship with FMS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.